# A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

> **NCT06908226** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Longboard Pharmaceuticals** · enrollment: 324 (estimated)

## Conditions studied

- Developmental and Epileptic Encephalopathy

## Interventions

- **DRUG:** LP352

## Key facts

- **NCT ID:** NCT06908226
- **Lead sponsor:** Longboard Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-02-12
- **Primary completion:** 2027-11-11
- **Final completion:** 2027-12-17
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06908226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06908226, "A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06908226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*